Verici Dx, a developer of advanced clinical diagnostics for organ transplant, announced that collaborators will present new data on the predictive performance of its Tutivia test at the American Transplant Congress (ATC) Annual Meeting. The event is scheduled to take place from June 20–24, 2026, in Boston. The presentations will focus on the test's ability to predict acute kidney transplant rejection, which is critical for optimizing patient management and outcomes.

The two poster presentations will be delivered by leading transplant clinicians. They will describe the capabilities of Tutivia, a blood-based transcriptomics laboratory developed test (LDT). The test is designed to support precise immunosuppression management by distinguishing rejection from other causes of graft injury, such as BK virus–associated nephropathy and ischemic–reperfusion injury. These conditions can confound conventional monitoring tools, including serum creatinine and cell-free DNA.

Presentation Details

The following table outlines the specific details of the poster presentations scheduled for Tuesday, June 23, 2026:

Verici Dx plc combines multiomic analyses with proprietary artificial intelligence to deliver predictive, actionable, data-driven intelligence. This approach reflects the complexity and heterogeneity of transplant patients, enabling clinicians to optimize therapy, guide biopsy decisions, and stratify risk with greater confidence. The company's lead product, Tutivia, is a post-kidney transplant test focused on the early detection of acute rejection.

3B BlackBio Dx reported a consolidated revenue of approximately INR142 crores with a Profit After Tax (PAT) of nearly INR60 crores for the financial year ended March 31, 2026. The company’s performance was driven by healthy growth in its diagnostic business and strong contributions from its subsidiaries, TRUPCR Europe and Coris BioConcept. Management has provided a revenue growth guidance of 15% to 20% for the upcoming financial year FY27.

The molecular diagnostic business in India grew by approximately 10%, recording sales of INR86.47 crores compared to INR78.34 crores in the previous year. This growth was attributed to increased penetration in government and private laboratories and an expanded distribution network. TRUPCR Europe achieved sales of GBP1.75 million, translating to INR20.67 crores, reflecting a consistent growth trajectory with a CAGR of approximately 40% over the last four years.

Coris BioConcept, acquired in August 2025, contributed consolidated sales of INR35.91 crores for the seven months post-acquisition, along with a PAT of INR8.76 crores. The company is currently focused on the US FDA submission process for selected Antimicrobial Resistance (AMR) products, which management believes will provide access to the significant US diagnostic market. Additionally, the Group is progressing with its In Vitro Diagnostic Regulation (IVDR) transition, having appointed BSI as its notified body and completed QMS audits.

Financial Performance

Looking ahead, the company aims to expand its global presence by strengthening distributor partnerships and entering new geographies across Europe, Africa, Asia Pacific, and Latin America. Management indicated that while domestic growth is expected to be around 15%, international operations are projected to grow between 20% and 25%. The company also maintains a strong cash position, with reserves being actively managed for potential mergers and acquisitions to support long-term expansion.